Our results provide strong rationale for the use of HR inhibitors, as well as ATRi (which are also known to indirectly suppress HR) in particle therapy to further sensitize tumor cells and also suggest the use of RAD52 and PARP1 inhibitors to further enhance efficacy. The gene discussed is PARP1; the disease is neoplasm.